Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells

Carlo Calissano,1 Rajendra N Damle,1,2 Sonia Marsilio,1 Xiao-Jie Yan,1 Sophia Yancopoulos,1 Gregory Hayes,3 Claire Emson,3 Elizabeth J Murphy,3,4 Marc K Hellerstein,3 Cristina Sison,3 Matthew S Kaufman,5 Jonathan E Kolitz,1,2 Steven L Allen,1,2 Kanti R Rai,1,6 Ivana Ivanovic,7 Igor M Dozmorov,7 Sergio Roa,8 Matthew D Scharff,8 Wentian Li,1 and Nicholas Chiorazzi1,2,9

1The Feinstein Institute for Medical Research, North Shore–LIJ Health System, Manhasset, New York, United States of America; 2Department of Medicine, North Shore University Hospital, North Shore–LIJ Health System, Manhasset, and Hofstra North Shore–LIJ School of Medicine, Hempstead, New York, United States of America; 3KineMed, Inc., Emeryville, California, United States of America; 4Department of Medicine, University of California, San Francisco, California, United States of America; 5Biostatistics Unit, The Feinstein Institute for Medical Research, North Shore–LIJ Health System, Manhasset, New York, United States of America; 6Department of Medicine, Long Island Jewish Medical Center, North Shore–LIJ Health System, New Hyde Park, and Hofstra North Shore–LIJ School of Medicine, Hempstead, New York, United States of America; 7Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America; 8Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York, United States of America; and 9Department of Molecular Medicine, Hofstra North Shore–LIJ School of Medicine, Hempstead, New York, United States of America

The failure of chemotherapeutic regimens to eradicate cancers often results from the outgrowth of minor subclones with more dangerous genomic abnormalities or with self-renewing capacity. To explore such intratumor complexities in B-cell chronic lymphocytic leukemia (CLL), we measured B-cell kinetics in vivo by quantifying deuterium (2H)-labeled cells as an indicator of a cell that had divided. Separating CLL clones on the basis of reciprocal densities of chemokine (C-X-C motif) receptor 4 (CXCR4) and cluster designation 5 (CD5) revealed that the CXCR4dimCD5bright (proliferative) fraction contained more 2H-labeled DNA and hence divided cells than the CXCR4brightCD5dim (resting) fraction. This enrichment was confirmed by the relative expression of two cell cycle–associated molecules in the same fractions, Ki-67 and minichromosome maintenance protein 6 (MCM6). Comparisons of global gene expression between the CXCR4dimCD5bright and CXCR4brightCD5dim fractions indicated higher levels of pro-proliferation and anti-apoptotic genes and genes involved in oxidative injury in the proliferative fraction. An extended immunophenotype was also defined, providing a wider range of surface molecules characteristic of each fraction. These intraclonal analyses suggest a model of CLL cell biology in which the leukemic clone contains a spectrum of cells from the proliferative fraction, enriched in recently divided robust cells that are lymphoid tissue emigrants, to the resting fraction enriched in older, less vital cells that need to immigrate to lymphoid tissue or die. The model also suggests several targets preferentially expressed in the two populations amenable for therapeutic attack. Finally, the study lays the groundwork for future analyses that might provide a more robust understanding of the development and clonal evolution of this currently incurable disease.

INTRODUCTION

Chronic lymphocytic leukemia (CLL) is a relatively frequent, incurable B-cell malignancy (1,2). Even though some patients live for long periods with the disease, many undergo progressive decline, leading to demise. Progression to a more aggressive disease is often associated with genomic changes (3), suggesting that clonal evolution is a key factor in the disease.

We previously found that CLL clones are composed of subpopulations of cells that proliferate at different rates (4), as measured by in vivo deuterium (2H)-incorporation into newly synthesized DNA of dividing cells (5,6). The most proliferative fraction of a cancer clone is of major interest for several reasons.
First, the “proliferative compartment” may contain cells that developed new structural DNA abnormalities leading to more lethal disease. Furthermore, the most recently born fraction may be progeny of putative leukemic stem cells. Finally, such cells would be potential targets for therapies to abort clonal evolution.

We therefore studied the kinetic complexity of individual CLL clones to decipher fundamental insights about the pathophysiology of the disease. In particular, we focused on further characterizing the proliferative and resting compartments using differences in the densities of a surface membrane molecule upregulated after normal B-cell activation (cluster designation 5 [CD5]) and another involved in maintaining B-cell contact with stromal elements of solid lymphoid tissues (chemokine [C-X-C motif] receptor 4 [CXCR4]). Using samples from patients for which CLL cells had been labeled in vivo with 2H2O, we divided clones into subfractions enriched in the most proliferative and most quiescent compartments. These fractions were then further characterized by comparing expression of genes encoding molecules usually upregulated in dividing or resting populations. Finally, to provide a robust membrane map of these compartments that might be used for further characterization and therapeutic targeting in patients, an extended surface phenotype was defined with a larger patient cohort.

MATERIALS AND METHODS

Patients
The Institutional Review Board of the North Shore–LIJ Health System approved these studies. After obtaining informed consent in accordance with the Declaration of Helsinki, venous blood was collected from randomly chosen CLL patients diagnosed by established criteria. A total of 15 subjects participating in the 2H2O protocols were studied. Patients drank 2H2O for 6–12 weeks, depending on the protocol, and cells were studied at two time points during this period.

2H Measurements by Gas Chromatography/Mass Spectrometry and Calculation of the Fraction of Labeled Cells
Peripheral blood mononuclear cells were separated from heparinized venous blood and leukocyte-enriched fractions by density gradient centrifugation using Ficoll-Paque (Pharmacia LKB Biotechnology, Piscataway, NJ, USA) and cryopreserved until use. Calculation of the fraction of newly divided cells was performed after determination of 2H enrichment in plasma or saliva and of 2H enrichment in deoxyadenosine of genomic DNA as described (4).

Isolation of Cell Fractions on the Basis of Expression of CXCR4 and CD5
Peripheral blood mononuclear cells were incubated with murine anti-human monoclonal antibodies (mAbs): CD5-FITC (fluorescein isothiocyanate), CXCR4-PE (phycoerythrin), CD3–peridinin-chlorophyll-protein (CD3-PerCP) and CD19–allophycocyanin (CD19-APC) (all from BD Biosciences, San Jose, CA, USA). After gating on CD19+CD3–CD5+ events, cells were sorted with a BD FACSAria™ (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA) on the basis of intensity of CXCR4 and CD5 (Figures 1A, B), and cell pellets were stored at −80°C until performing gas chromatography/mass spectrometry or RNA extraction.

Gene Expression Profiling and Gene Expression Data Analyses
The quality of RNA extracted from sorted cells using the RNeasy minikit (Qiagen, Valencia, CA, USA) was assessed using an Agilent RNA 6000 Pico Kit (Agilent Technologies, Colorado Springs, CO, USA). A total of 50 ng total RNA was subjected to first- and second-strand reverse transcription followed by a single in vitro transcription amplification that incorporated biotin-labeled nucleotide to yield biotinylated antisense RNA (a-RNA) using a TargetAmp Nano-g Biotin-aRNA labeling kit (Epicycle Biotechnologies, Madison, WI, USA). Purified a-RNA was quantified, and the fragment size was ascertained on a Bioanalyzer (Agilent Technologies) using an Agilent RNA 6000 Nano Kit. Labeled a-RNA was hybridized to a Human WG-6 v3.0 Expression BeadChip containing 48,804 probes and stained using streptavidin-Cy3 as per the manufacturer’s instructions. The signal generated was detected by high-performance laser optics of the BeadArray Reader (Illumina, San Diego, CA, USA). Data were normalized using quantile normalization by BeadStudio software (Illumina). To determine differentially expressed genes, the CXCR4dimCD5bright versus CXCR4bright CD5dim expression value ratio was computed for each patient and log-transformed, and a Student t test was performed using R (www.Rproject.org). Significant gene differences had 1.3 or greater fold change and P < 0.01; for fold change, we used the nth root of the product of all individual ratios, or the geometric mean of the ratio, for n samples.

Genes were assigned to specific functional categories using Ingenuity Pathway Analysis (IPA, www.ingenuity.com), Panther Classification System (Panther, www.pantherdb.org), DAVID Bioinformatics Resources 6.7, National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH) (DAVID, http://david.abcc.ncifcrf.gov/home.jsp) and GeneCards Batch Queries (GeneALaCart, www.genecards.org/BatchQueries/index.php). Significantly different gene expression values were clustered hierarchically on the basis of average linkage on a correlation-based distance (defined at http://arxiv.org/abs/cs/0402061). Heatmaps of gene expression values for identified relevant functional categories were generated using heatmap.2 in the gplots package of R.

Measurements of Surface and Intracellular Antigens by Flow Cytometry
Peripheral blood mononuclear cells were incubated with different combinations of murine anti-human mAbs directly conjugated with the indicated fluo-
intracellular marker was determined and compared.

All supplementary materials are available online at www.molmed.org.

RESULTS

CLL clones can be divided into distinct fractions on the basis of inverse surface expression of CXCR4 and CD5. By screening a panel of chemokine receptors expressed on clones from a series of CLL patients (4), we found an inverse relationship between CXCR4 and CD5 densities, with differing shapes among patients (Figures 1A–D). The abundance of cells representing the extremes of these two populations (CXCR4dimCD5bright versus CXCR4brightCD5dim) was relatively small and varied between patients (1–8%, not shown), with the majority of cells (>90%) falling into an intermediate category (CXCR4intCD5int; Figures 1A–D).

We reasoned that high CD5 density would reflect cellular activation as in normal human B cells (7), and low CXCR4 levels would identify cells that internalized the receptor because of an activation event and thereby passed from a lymphoid tissue to the periphery (8). As detailed elsewhere (5), incorporation of 2H into cellular DNA in patients given 2H2O is a direct measure of newly synthesized DNA and hence cell division, thereby allowing study of birth rates of CLL cells in vivo (6,9,10). Therefore, we sorted CLL cells from nine patients consuming 2H2O (Figure 1E) into three fractions and quantified 2H-labeled deoxyadenosine in each fraction by gas chromatography/mass spectrometry. This step indicated that at 21 d, the CXCR4dimCD5bright fraction was markedly enriched in divided cells compared with the remainder of the clone, and this result lasted through 42 d (Figure 1F); this disparity was reflected by significantly different CXCR4dimCD5bright to CXCR4brightCD5dim enrichment ratios at the two time points (12.6 at 21 d and 10.9...
These findings were verified by analyzing ex vivo, in the CXCR4/CD5 fractions, two cell cycle–related molecules, Ki-67 and MCM6, both expressed from the G1 to M phase. Comparisons of CXCR4^{dim}CD5^{bright} versus CXCR4^{int}CD5^{int} versus CXCR4^{bright}CD5^{dim} fractions in an expanded cohort of CLL patients were significantly different (P < 0.01) for both Ki-67 and MCM6 (Figures 1H–I).

Collectively, these in vivo and ex vivo findings indicate that the CXCR4^{dim} CD5^{bright} and CXCR4^{bright}CD5^{dim} fractions of CLL clones are highly enriched compared with the total circulating leukemic load, in recently divided/young and more resting/older members, respectively. For simplicity, we refer to these as the “proliferative” and “resting” compartments going forward, even though the dominant intermediate population contributes cells with similar phenotypes to a significant extent.

**Proliferative and Resting Fractions Exhibit Gene Expression Differences Consistent with Their Putative Contrasting Proliferative Histories**

Global gene expression profiling (GEP) was performed on isolated fractions from the same patients. Using Illumina HumanWG-6 v3.0 expression arrays to measure the relative expression of 25,440 genes and selecting genes for ≥1.3-fold difference in expression and P ≤ 0.01, we defined 1,299 genes differentially expressed between the two compartments; 715 genes were more highly expressed in the proliferative and 584 in the resting fraction (Supplementary Table 1). These genes were then segregated into categories that would support their difference in time from cellular activation and division and in migratory capacities using a number of bioinformatic programs and databases (see Materials and Methods).

**Genes involved in cell proliferation.**

We determined the extent that the two fractions differed in expression of genes...
involved in normal or abnormal cell proliferation. Consistent with the CXCR4<sup>dim</sup>CD5<sup>bright</sup> fraction being enriched in divided cells, 20 pro-proliferation genes were found in this compartment (Figure 2A, top) and 10 in the CXCR4<sup>bright</sup>CD5<sup>dim</sup> fraction. In contrast, a larger number of genes with an antiproliferation function were found in the CXCR4<sup>dim</sup>CD5<sup>bright</sup> fraction than the CXCR4<sup>dim</sup>CD5<sup>bright</sup> fraction (12 genes versus 7; Figure 2A, bottom).

Among the pro-proliferation genes upregulated in the CXCR4<sup>dim</sup>CD5<sup>bright</sup> fraction were two canonical molecules involved in cell cycle progression: Cyclin E1 (CCNE1) and cyclin D2 (CCND2). CCND2 plus Ki-67 and MCM6, which were enriched in this fraction on the basis of flow cytometry (Figure 3), have been found higher in CLL lymph nodes than peripheral blood (11). Notably, of the pro-proliferation genes that were higher in resting cells (Figure 2A, top), myocyte-specific enhancer factor 2C (MEF2C) and midkine (MDK; neurite growth-promoting factor 2) promote growth of cell types that are often in a resting state: hematopoietic progenitors (12) and embryonic stem cells (13), respectively.

Of the antiproliferative genes higher in the CXCR4<sup>bright</sup>CD5<sup>dim</sup> fraction (Figure 2A, bottom), BCL6, BACH2 and RGS2 are of interest because they control checkpoints in B-cell activation and maturation (14–16).

**Genes involved in cell survival.** Recently born/divided cells would also likely receive prosurvival/antiapoptotic signals, whereas cells of the resting compartment would be less likely to receive these, being temporally further from an activation signal and trophic support of tissue microenvironments. A total of 25 antiapoptotic genes are higher in the proliferative versus 8 in the resting fraction (Figure 2B, bottom). Of note, MEF2C appears necessary for B-cell proliferation and survival after in vitro B-cell receptor (BCR) stimulation (17). Several genes upregulated in the resting fraction are of interest. TNF receptor superfamily 13C (TNFRSF13C) is the receptor for the B-cell activating factor that mediates survival in normal and non-Hodgkin lymphoma B lymphocytes (18,19). TNFRSF15 codes a ligand for TNFRSF25 and TNFRSF6B that is not known to be expressed in B cells and that inhibits growth in other cells (20). Finally, interleukin (IL)-4R, which promotes normal B-cell and CLL cell survival (21) and proliferation (22) and is expressed by CLL cells (23), is upregulated in this fraction.

Prodeath genes are slightly more abundant in the resting fraction, suggesting that this compartment contains older, less robust cells (Figure 2B, top). For example, harakiri (HRK), forkhead box O3 (FOXO3) and leptin (LEP) (24–26) stimulate apoptosis in various cell types, and transmembrane 123 (TMEM123) encodes a mucinlike gene that leads to oncotic cell death upon cross-linking (27).

**Genes involved in oxidative injury.** Cells of the proliferative fraction upregulated more genes involved in the generation or repair of oxidative injury than in resting cells (27 genes versus 6; Figure 2C), likely because of increased metabolic activity in the dividing/recently divided cells. In addition, oxidative injury is a known feature of CLL cells (28).

**Figure 3.** Extended immunophenotype of proliferative and resting CLL fractions. Surface markers were analyzed by flow cytometry in CXCR4<sup>dim</sup>CD5<sup>bright</sup> (X) and CXCR4<sup>bright</sup>CD5<sup>dim</sup> (G) fractions. All surface molecules are depicted but CCR7 and CTLA4 were greater in CXCR4<sup>dim</sup>CD5<sup>bright</sup> fractions, in terms of percent positive cells (A) or mean fluorescence intensity (B) or both. CCR7 and CTLA4 are higher in the CXCR4<sup>bright</sup>CD5<sup>dim</sup> fraction. *P < 0.01 and †P < 0.05 (paired Student t test).

**Products of catalase (CAT), glucose-6-phosphate dehydrogenase (G6PD), glutathione peroxidase 1 (GPX1), heme oxygenase (decycling) 1 (HMOX1) and thioredoxin (TXN) have a role in scavenging free radicals.**

**Genes involved in cell trafficking.** Lastly, 33 trafficking-related molecules were expressed at higher levels in the proliferative and 8 in the resting fractions (Figure 2D). Consistent with cells of the proliferative compartment having recently exited lymphoid tissues is the heightened expression of integrin, beta 7 (ITGB7) and CXCR3. ITGB7 remains on the surface of cells after leaving solid tissues and is involved in passage of cells into mucosa-associated lymphoid tissues (29,30); CXCR3 is involved in CLL cell migration along interferon (IFN)-inducible protein 10 and IFN-γ-induced monokine gradients (31). However, a number of other genes do not readily fit the profile of recent emigrants of lymphoid tissues. In particular, overexpression of adhesion molecules platelet endothelial cell adhesion molecule 1 (PECAM1), cluster designation 11A (lymphocyte function-associated antigen 1)/integrin, alpha L (CD11a/ITGAL) and cluster...
expression levels of confirmed as significantly different between the two fractions (Supplementary Figure 2). Expression levels of CD5 and CXCR4 served as internal controls.

Surface Molecules Further Distinguish the Proliferative and Resting Compartments

Finally, to permit an even more precise definition of the two fractions in CLL and to define molecules that might be valuable therapeutic targets for these fractions, the CXCR4/C5 subsets were subjected to a detailed multiparameter phenotypic analysis (Figures 3A, B). Molecules were studied because they are markers of B-cell activation, survival and migration or are targets of mAbs in use in humans. The proliferative compartment contained significantly more cells that expressed, at higher densities, CD38, CD20, CD23, CD27, CD52, JML-1, DR5, CXCR3, CD49d, CD62L, CD11a and CD11c (Figures 3A, B). Only ROR-1, FcyRIIB and BAFF-R exhibited differences solely on the basis of density. Two molecules were higher in the resting compartment: CCR7 (both in the percent of positive cells and intensity) and CTLA4 (intensity). It is noteworthy that several of these molecules are targets of mAbs or compounds already in clinical use (35–41) or are being tested in human subjects (23,42–46).

DISCUSSION

The aim of this study was to further delineate and isolate cells with different kinetics in CLL clones, focusing on cells that had recently divided or are resting. Using [3H]-incorporation into newly synthesized DNA of dividing cells as a measure of proliferation, we previously demonstrated intraclonal kinetic complexity in CLL, defining a small population (~0.1–1% of the leukemic clone) that divided daily (6). Because the [3H]-incorporation approach does not permit visualization of individual cells that have divided, we subsequently enrich for cells of the proliferative fraction using surface expression of a candidate molecule, CD38, that is expressed on activated human B cells (47) and is associated with poor clinical outcome in CLL (48). These studies indicated that within each CLL clone, the CD38+ fraction contained ~2.5 times more recently divided cells than the CD38− fraction (4). In the present study, using differential surface membrane densities of CXCR4 and CD5, we isolated fractions differing by ~11-fold in the percentage of recently divided cells (Figure 1G). In line with our previous study, CD38 expression was

**Figure 4.** Hypothetical model of the lifecycle of a CLL B cell. Part 1: CLL cells rest on the stroma because of at least CXCR4-CXCL12 interactions. When stimulated, cells are activated and divide, upregulating CD5, internalizing CXCR4 and detaching from stroma. The process could be ligand-induced (for example, BCR or toll-like (TLR) or other pathways) or spontaneous. Low CXCR4 levels increase the chances of recently divided CLL cells (CXCR4dimCD5bright phenotype) exiting solid tissue and reaching peripheral blood. Part 2: Recently born/divided CLL cells reach peripheral blood as members of the CXCR4brightCD5dim fraction. Over time, possibly because of a lack of trophic input from the solid tissue microenvironment, cells begin to reexpress CXCR4 to trek back to nutrient-rich niches. This leads to expression of a CXCR4intCD5int and then CXCR4brightCD5dim membrane phenotype. The model considers the three fractions to be linked as a continuum. Part 3: CXCR4brightCD5int CLL cells have the greatest chance of detecting and following a CXCL12/SDF1 gradient, thereby reentering lymphoid solid tissue and receiving prosurvival stimuli. Those that do not reenter die by exhaustion.

**Figure 3.** Designation 11c/integrin, alpha X (complement component 3 receptor 4 subunit) (CD11c/ITGAX), the latter two of which were confirmed by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) (Supplementary Figure 2) and flow cytometry (Figure 3), seems paradoxical, since these are usually expressed on cells docking on the endothelium and exiting the circulation.

Cells of the resting compartment expressed more pleckstrin homology domain containing, family A member 2 (PLEKHA2) mRNA (Figure 2D) and CCR7 and CTLA4 protein (Figure 3). CCR7 promotes homing of normal B lymphocytes and CLL cells to lymph nodes and mediates neoplastic B-cell homing in patients with widespread nodal dissemination (32). Also, CCR7 and CXCR4 promote metastasis of solid tumors (33). PLEKHA2 has been found to be highly expressed in poor outcome CLL cells (unmutated IGHV or high ZAP-70 levels) and to have a role in adhesion to fibronectin and laminin (34).

qRT-PCR Analyses of Selected Genes Confirm Their Overexpression in Proliferative or Resting Fractions

We performed qRT-PCR for genes coding molecules expressed on or at B-cell surfaces to provide a guide for developing an extended surface membrane phenotype and to corroborate the GEP data. A total of 67.8% (38/56) of genes were confirmed as significantly different between the two fractions (Supplementary Figure 2). Expression levels of CD5 and CXCR4 served as internal controls.
significantly higher in the CXCR4<sup>dim</sup> CD5<sup>bright</sup> proliferative subset (Figure 3A). Finding increased numbers of cells expressing Ki-67 and MCM6 in the same fraction confirmed the accuracy of this approach (Figures 1H, I). Finally, global GEP on the same CXCR4/CX5 subsets further validated that our approach identified subsets of CLL clones differing in proliferative histories, since the CXCR4<sup>dim</sup>CD5<sup>bright</sup> fraction overexpressed more genes that support cell division (Figure 2A), block apoptosis (Figure 2B) and induce/repair oxidative damage (Figure 2C) than the resting fraction, which contained more genes that inhibit cell division (Figure 2A) and survival (Figure 2B). Nevertheless, these fractions remain heterogeneous, likely containing cells from the intermediate fraction with characteristics distinct from those we are describing. Thus, the situation is complex, and a more expansive collection and analysis of such data will better elucidate unique features of the two compartments. Still, the detection of gene (Figure 2) and protein (Figures 1 and 3) expression differences consistent with recently divided and resting cells, combined with the direct in vivo demonstration of significant enrichment in cycled cells in the proliferative fraction and a markedly reduced abundance in the resting fraction (Figure 1), confirm that using CXCR4/CX5 densities on CD19<sup>+</sup> cells is a major improvement in the delineation of these two compartments.

The data conjure a lifecycle for individual CLL cells representing a continuum between the CXCR4<sup>dim</sup>CD5<sup>bright</sup>, CXCR4<sup>dim</sup>CD5<sup>int</sup> and CXCR4<sup>bright</sup>CD5<sup>dim</sup> fractions (Figure 4). At one extreme is the proliferative fraction, highly enriched in young, vital cells that recently left a solid lymphoid tissue where activation and proliferation occurred. At the other end is the resting compartment, containing older, less robust cells that may have been circulating in the periphery longer and are attempting through high CXCR4 levels to migrate into a solid tissue niche to avoid death. In this model, the intermediate fraction, which is the bulk of the clone, links the extremes and is the fraction from which most of our current knowledge on circulating CLL cells is derived. This relationship is supported by the fact that BCR stimulation leads to downregulation of CXCR4 expression (49), as depicted in Figure 4, part 1. Although our data are consistent with this model, the process remains hypothetical because we have only studied cells in the peripheral circulation. Notably, it was recently shown by comparative GEP of bone marrow and lymph node cells that lymph nodes may host most of the CLL proliferative events (11). In our study, cells with low CXCR4 and high CD5 levels could include emigrants from any site, and only one of the differentially expressed molecules involved in trafficking that we defined is site specific: ITGB7 suggests specific passage to mucosa-associated lymphoid tissues. Considering that at least some CLL cells may be derived from a human B-1 cell equivalent (50,51), the potential of migration to such tissues, which is favored for murine B-1 cells (52), is provocative.

This hypothetical lifecycle also suggests “stem-like” or “initiating” capabilities of CLL subclones (53). For instance, the CXCR4<sup>bright</sup>CD5<sup>dim</sup> cells could be nested on stromal elements (Figure 4, part 1) before being released and giving rise to the dividing CXCR4<sup>dim</sup>CD5<sup>bright</sup> cells of the proliferative and bulk fractions (Figure 4, part 2); therefore, these CXCR4<sup>bright</sup>CD5<sup>dim</sup> resting cell fractions could be a distinct self-renewing subset from which all clonal members emanate. In a related scenario, these same cells could be members of the CXCR4<sup>bright</sup>CD5<sup>dim</sup> fraction of the resting compartment of the blood on their way back to a sustaining niche in a lymphoid tissue (Figure 4, part 3), where they might divide again. The former possibility would be consistent with a B-1–like cell, because in mice these cells have self-renewal capacity (54), implying that the ability to migrate effectively would be the key factor determining survival of the clone. If the latter possibility is the case, a careful analysis of the resting compartment might yield a subset of cells with stem-like/initiating capacities.

Delineation of intratumor kinetic heterogeneity may also have therapeutic implications. Although most anticancer therapies are predicated on eliminating the entire neoplastic clone, preferentially targeting the proliferative and resting compartments might be efficacious. Thus, preferentially eliminating the most recently born/divided cells would limit the fount of clonal evolution; preventing cells from reentering solid tissue would thwart the less robust, apoptosis-prone resting cells from receiving survival signals. Collectively, these approaches would lock a clone into a steady state of genetic abnormalities and eventually lead to clonal shrinkage based on spontaneous cell death (6,55) and death due to survival signal deprivation (56).

Although speculative, this approach could be tested, since relevant compounds are already in clinical use or evaluation. For example, the proliferative compartment expresses higher levels of CD20, CD23, CD49d, CD52, CD11a and DR5 (Figure 3), all of which can be targeted by specific, available mAbs (23,35–46). Other targets of potential interest in the proliferative fraction are CXCR3 (GEP, qRT-PCR, flow), CD27 (flow), ITGB7 (GEP and qRT-PCR), Ly96 (GEP), CD62L (flow) and CD11c/ITGAX (flow and GEP). For the resting compartment, the most relevant molecules appear to be CXCR4 and CCR7 (flow and GEP). Plerixaflor, a CXCL12 (CXCR4 ligand) inhibitor used for stem cell mobilization, is being tested in CLL treatment (39). Although no compound is presently available to target CCR7 in vivo, an anti-CCR7 mAb kills CLL cells in vitro without affecting T cells that also express CCR7 (57). Thus, an anti-CXCR4 and/or anti-CCR7 approach could limit the ability of CXCR4<sup>bright</sup> and CCR7<sup>bright</sup> cells to reenter solid tissues, fostering resting compartment apoptosis. Finally, targeting IL-4R and CTLA4 is feasible because
a recombinant IL-4–Pseudomonas exotoxin fusion protein that binds IL-4R (23) and overcomes apoptosis resistance of CLL cells (58) is in clinical use, and mAbs reactive with CTLA4 (40,41) are currently being used to potentiate T-cell responses against tumors (59).

ACKNOWLEDGMENTS
This work was supported in part by the National Cancer Institute / NIH (CA81554) and by philanthropic contributions from The Karches Foundation, Prince Family Foundation, Marks Foundation, Jerome Levy Foundation, Leon Levy Foundation, Andrew and Mona Albert Fund Inc., and Joseph Elett Leukemia Research Fund. We thank Aarti Damle and The Feinstein Institute’s microarray core facility for gene expression analyses.

DISCLOSURE
The authors declare that they have no competing interests as defined by Molecular Medicine, or other interests that might be perceived to influence the results and discussion reported in this paper.

REFERENCES
1. Chiorazzi N, Rai KR, Ferrari M. (2005) Chronic lymphocytic leukaemia. N. Engl. J. Med. 352:804–15.
2. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. (2010) From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat. Rev. Cancer. 10:37–50.
3. Shanafelt TD, Grogg DJ, Smith JR, Loken MR, Abboud CF, Kantarjian H, Garcia-Manero G, Cutler S, Lasho TL, Lad婆 ME, Kantarjian H, Garcia-Manero G, Cutler S, Lasho TL, Lad婆 ME. (2009) BAFF-R promotes cell proliferation and survival in murine B lymphocytes and ability to activate B cells. J. Clin. Invest. 120:27–36.
4. Zlotnik A, Burkhardt AM, Homey B. (2011) CXCR3: a novel G protein-coupled receptor on malignant B cells and mediates chemotaxis. J. Clin. Invest. 121:404–12.
5. Stehling-Sun S, Dade J, Nutt SL, DeKoter RP, Stehling-Sun S, Dade J, Nutt SL, DeKoter RP, Kappos L, et al. (2011) Natalizumab treatment for refractory chronic lymphocytic leukemia. Blood. 117:6365–41.
6. Nightingale G. (2011) Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia. Ann. Pharmacother. 45:1248–55.
7. Rai KR, et al. (2002) Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J. Clin. Oncol. 20:3891–7.
8. Calissano P, et al. (2011) Nalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 10:745–58.
9. Nightingale G. (2011) Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia. Ann. Pharmacother. 45:1248–55.
10. Rai KR, et al. (2002) Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J. Clin. Oncol. 20:3891–7.
41. Callahan MK, Wolchok JD, Allison JP. (2010) Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin. Oncol. 37:473–84.

42. Bajaj M, Heath EI. (2011) Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults. Expert Opin. Biol. Ther. 11:1519–24.

43. Byrd JC, et al. (2007) Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin. Cancer Res. 13:4448–55.

44. Burger M, et al. (2005) Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 106:1824–30.

45. Puri S, et al. (2009) A review of studies on targeting interleukin 4 receptor for central nervous system malignancy. Curr. Mol. Med. 9:732–9.

46. de Weers M, et al. (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 186:1840–8.

47. Pascual V, et al. (1994) Analysis of somatic mutation in five B cell subsets of human tonsil. J. Exp. Med. 180:329–39.

48. Damle RN, et al. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 94: 1840–7.

49. Quirós MP, Burger JA. (2010) BCR-mediated decrease of CXCR4 and CD62L in CLL. Cancer Res. 70:5194; author reply 5195.

50. Chiorazzi N, Ferrarini M. (2011) Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood. 117:1781–91.

51. Griffin DO, Holodick NE, Rothstein TL. (2011) Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+CD27+CD43+CD70. J. Exp. Med. 208:67–80.

52. Fagarasan S, et al. (2000) Mechanism of B1 cell differentiation and migration in GALT. Curr. Top. Microbiol. Immunol. 252:221–9.

53. Dick JE. (2008) Stem cell concepts renew cancer research. Blood. 112:4793–807.

54. Hayakawa K, Hardy RR, Herzenberg LA, Herzenberg LA. (1985) Progenitors for Ly-1 B cells are distinct from progenitors for other B cells. J. Exp. Med. 161:1354–68.

55. Chiorazzi N. (2007) Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract. Res. Clin. Haematol. 20:399–413.

56. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. (2009) The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 114:3367–75.

57. Alfonso-Perez M, et al. (2006) Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia. J. Leukoc. Biol. 79:1157–65.